PF-06801591
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for PF-06801591, covering 2021-12-13 to 2021-12-13. Get the full timeline:
Most recent: Clinical Trial Update: A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors [Phase 1]